BICARA THERAPEUTICS INC (BCAX) Stock Price & Overview
NASDAQ:BCAX • US0554771032
The current stock price of BCAX is 18.47 USD. Today BCAX is down by -0.16%. In the past month the price increased by 22.32%. In the past year, price increased by 11.6%.
BCAX Key Statistics
- Market Cap
- 1.012B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.24
- Dividend Yield
- N/A
BCAX Stock Performance
BCAX Stock Chart
BCAX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BCAX. When comparing the yearly performance of all stocks, BCAX turns out to be only a medium performer in the overall market: it outperformed 60.65% of all stocks.
BCAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCAX. While BCAX has a great health rating, there are worries on its profitability.
BCAX Earnings
BCAX Forecast & Estimates
18 analysts have analysed BCAX and the average price target is 29.86 USD. This implies a price increase of 61.66% is expected in the next year compared to the current price of 18.47.
BCAX Groups
Sector & Classification
BCAX Financial Highlights
Over the last trailing twelve months BCAX reported a non-GAAP Earnings per Share(EPS) of -2.24. The EPS decreased by -302.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.61% | ||
| ROE | -30.17% | ||
| Debt/Equity | 0 |
BCAX Ownership
BCAX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCAX
Company Profile
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Company Info
BICARA THERAPEUTICS INC
116 Huntington Avenue Suite 703
Boston MASSACHUSETTS US
Employees: 55
Phone: 16174684219
BICARA THERAPEUTICS INC / BCAX FAQ
What does BICARA THERAPEUTICS INC do?
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
What is the stock price of BICARA THERAPEUTICS INC today?
The current stock price of BCAX is 18.47 USD. The price decreased by -0.16% in the last trading session.
Does BCAX stock pay dividends?
BCAX does not pay a dividend.
How is the ChartMill rating for BICARA THERAPEUTICS INC?
BCAX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of BICARA THERAPEUTICS INC (BCAX) based on its PE ratio?
BICARA THERAPEUTICS INC (BCAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.24).
When does BICARA THERAPEUTICS INC (BCAX) report earnings?
BICARA THERAPEUTICS INC (BCAX) will report earnings on 2026-03-26.
Can you provide the short interest for BCAX stock?
The outstanding short interest for BICARA THERAPEUTICS INC (BCAX) is 19.56% of its float.